Cargando…
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors
Background: Cardiovascular adverse events (CV-AEs) are considered critical complications in chronic myeloid leukemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (TKIs). The aim of our study was to assess the correlation between metabolic profiles and CV-AEs in...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231160/ https://www.ncbi.nlm.nih.gov/pubmed/32326001 http://dx.doi.org/10.3390/jcm9041180 |
_version_ | 1783535126921084928 |
---|---|
author | Caocci, Giovanni Deidda, Martino Noto, Antonio Greco, Marianna Simula, Maria Pina Mulas, Olga Cocco, Daniele Fattuoni, Claudia Mercuro, Giuseppe La Nasa, Giorgio Cadeddu Dessalvi, Christian |
author_facet | Caocci, Giovanni Deidda, Martino Noto, Antonio Greco, Marianna Simula, Maria Pina Mulas, Olga Cocco, Daniele Fattuoni, Claudia Mercuro, Giuseppe La Nasa, Giorgio Cadeddu Dessalvi, Christian |
author_sort | Caocci, Giovanni |
collection | PubMed |
description | Background: Cardiovascular adverse events (CV-AEs) are considered critical complications in chronic myeloid leukemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (TKIs). The aim of our study was to assess the correlation between metabolic profiles and CV-AEs in CML patients treated with TKIs. Methods: We investigated 39 adult CML patients in chronic-phase (mean age 49 years, range 24–70 years), with no comorbidities evidenced at baseline, who were consecutively identified with CML and treated with imatinib, nilotinib, dasatinib, and ponatinib. All patients performed Gas-Chromatography-Mass-Spectrometry-based metabolomic analysis and were divided into two groups (with and without CV-AEs). Results: Ten CV-AEs were documented. Seven CV-AEs were rated as 3 according to the Common Toxicity Criteria, and one patient died of a dissecting aneurysm of the aorta. The patients’ samples were clearly separated into two groups after analysis and the main discriminant metabolites were tyrosine, lysine, glutamic acid, ornithine, 2-piperdinecarboxylic acid, citric acid, proline, phenylalanine, threonine, mannitol, leucine, serine, creatine, alanine, and 4-hydroxyproline, which were more abundant in the CV-AE group. Conversely, myristic acid, oxalic acid, arabitol, 4-deoxy rithronic acid, ribose, and elaidic acid were less represented in the CV-AE group. Conclusions: CML patients with CV-AEs show a different metabolic profile, suggesting probable mechanisms of endothelial damage. |
format | Online Article Text |
id | pubmed-7231160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72311602020-05-22 Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors Caocci, Giovanni Deidda, Martino Noto, Antonio Greco, Marianna Simula, Maria Pina Mulas, Olga Cocco, Daniele Fattuoni, Claudia Mercuro, Giuseppe La Nasa, Giorgio Cadeddu Dessalvi, Christian J Clin Med Article Background: Cardiovascular adverse events (CV-AEs) are considered critical complications in chronic myeloid leukemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (TKIs). The aim of our study was to assess the correlation between metabolic profiles and CV-AEs in CML patients treated with TKIs. Methods: We investigated 39 adult CML patients in chronic-phase (mean age 49 years, range 24–70 years), with no comorbidities evidenced at baseline, who were consecutively identified with CML and treated with imatinib, nilotinib, dasatinib, and ponatinib. All patients performed Gas-Chromatography-Mass-Spectrometry-based metabolomic analysis and were divided into two groups (with and without CV-AEs). Results: Ten CV-AEs were documented. Seven CV-AEs were rated as 3 according to the Common Toxicity Criteria, and one patient died of a dissecting aneurysm of the aorta. The patients’ samples were clearly separated into two groups after analysis and the main discriminant metabolites were tyrosine, lysine, glutamic acid, ornithine, 2-piperdinecarboxylic acid, citric acid, proline, phenylalanine, threonine, mannitol, leucine, serine, creatine, alanine, and 4-hydroxyproline, which were more abundant in the CV-AE group. Conversely, myristic acid, oxalic acid, arabitol, 4-deoxy rithronic acid, ribose, and elaidic acid were less represented in the CV-AE group. Conclusions: CML patients with CV-AEs show a different metabolic profile, suggesting probable mechanisms of endothelial damage. MDPI 2020-04-20 /pmc/articles/PMC7231160/ /pubmed/32326001 http://dx.doi.org/10.3390/jcm9041180 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Caocci, Giovanni Deidda, Martino Noto, Antonio Greco, Marianna Simula, Maria Pina Mulas, Olga Cocco, Daniele Fattuoni, Claudia Mercuro, Giuseppe La Nasa, Giorgio Cadeddu Dessalvi, Christian Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors |
title | Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors |
title_full | Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors |
title_fullStr | Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors |
title_full_unstemmed | Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors |
title_short | Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors |
title_sort | metabolomic analysis of patients with chronic myeloid leukemia and cardiovascular adverse events after treatment with tyrosine kinase inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231160/ https://www.ncbi.nlm.nih.gov/pubmed/32326001 http://dx.doi.org/10.3390/jcm9041180 |
work_keys_str_mv | AT caoccigiovanni metabolomicanalysisofpatientswithchronicmyeloidleukemiaandcardiovascularadverseeventsaftertreatmentwithtyrosinekinaseinhibitors AT deiddamartino metabolomicanalysisofpatientswithchronicmyeloidleukemiaandcardiovascularadverseeventsaftertreatmentwithtyrosinekinaseinhibitors AT notoantonio metabolomicanalysisofpatientswithchronicmyeloidleukemiaandcardiovascularadverseeventsaftertreatmentwithtyrosinekinaseinhibitors AT grecomarianna metabolomicanalysisofpatientswithchronicmyeloidleukemiaandcardiovascularadverseeventsaftertreatmentwithtyrosinekinaseinhibitors AT simulamariapina metabolomicanalysisofpatientswithchronicmyeloidleukemiaandcardiovascularadverseeventsaftertreatmentwithtyrosinekinaseinhibitors AT mulasolga metabolomicanalysisofpatientswithchronicmyeloidleukemiaandcardiovascularadverseeventsaftertreatmentwithtyrosinekinaseinhibitors AT coccodaniele metabolomicanalysisofpatientswithchronicmyeloidleukemiaandcardiovascularadverseeventsaftertreatmentwithtyrosinekinaseinhibitors AT fattuoniclaudia metabolomicanalysisofpatientswithchronicmyeloidleukemiaandcardiovascularadverseeventsaftertreatmentwithtyrosinekinaseinhibitors AT mercurogiuseppe metabolomicanalysisofpatientswithchronicmyeloidleukemiaandcardiovascularadverseeventsaftertreatmentwithtyrosinekinaseinhibitors AT lanasagiorgio metabolomicanalysisofpatientswithchronicmyeloidleukemiaandcardiovascularadverseeventsaftertreatmentwithtyrosinekinaseinhibitors AT cadeddudessalvichristian metabolomicanalysisofpatientswithchronicmyeloidleukemiaandcardiovascularadverseeventsaftertreatmentwithtyrosinekinaseinhibitors |